Illumina Collaborating With Pharmaceutical Firms on KRAS Cancer Diagnostics
MT Newswires Live
Sep 23, 2025
Illumina (ILMN) said Tuesday it is working with several global drugmakers to develop companion diagnostics on its TruSight Oncology test to target KRAS mutations.
The company said the partnerships aim to expand diagnostic claims that can help match cancer patients with targeted treatments and clinical trials.
KRAS is among the most frequently altered oncogenes, and identifying its variants is considered critical for selecting appropriate therapies, according to the company.
Illumina said the initiative builds on its pipeline of companion diagnostics under development with pharmaceutical companies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.